301 related articles for article (PubMed ID: 34811916)
1. Drug eruptions with novel targeted therapies - immune checkpoint and EGFR inhibitors.
Pospischil I; Hoetzenecker W
J Dtsch Dermatol Ges; 2021 Nov; 19(11):1621-1643. PubMed ID: 34811916
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor-related dermatologic adverse events.
Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
4. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors.
Storgard R; Markova A
J Allergy Clin Immunol Pract; 2024 May; 12(5):1132-1136. PubMed ID: 38548170
[TBL] [Abstract][Full Text] [Related]
6. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Lacouture M; Sibaud V
Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.
Kaunitz GJ; Loss M; Rizvi H; Ravi S; Cuda JD; Bleich KB; Esandrio J; Sander I; Le DT; Diaz LA; Brahmer JR; Drake CG; Hollmann TJ; Lacouture ME; Hellmann MD; Lipson EJ; Taube JM
Am J Surg Pathol; 2017 Oct; 41(10):1381-1389. PubMed ID: 28817405
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous immune-related adverse events to checkpoint inhibitors.
Malviya N; Tattersall IW; Leventhal J; Alloo A
Clin Dermatol; 2020; 38(6):660-678. PubMed ID: 33341200
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS
J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
[TBL] [Abstract][Full Text] [Related]
10. Clindamycin-induced Maculopapular Exanthema with Preferential Involvement of Striae Distensae: A Koebner phenomenon?
Monteagudo B; Cabanillas M; Iriarte P; Ramírez-Santos A; León-Muinos E; González-Vilas D; Suárez-Amor Ó
Acta Dermatovenerol Croat; 2018 Apr; 26(1):61-63. PubMed ID: 29782303
[TBL] [Abstract][Full Text] [Related]
11. A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution.
Masterson WM; Brown AM; Al Ameri MA; Patel AB
Cancer Treat Res Commun; 2022; 30():100506. PubMed ID: 34990901
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous adverse events caused by immune checkpoint inhibitors.
Quach HT; Johnson DB; LeBoeuf NR; Zwerner JP; Dewan AK
J Am Acad Dermatol; 2021 Oct; 85(4):956-966. PubMed ID: 34332798
[TBL] [Abstract][Full Text] [Related]
13. [Cutaneous Toxicity of Immune Checkpoint Inhibitors: A Narrative Review].
Gomes N; Sibaud V; Azevedo F; Magina S
Acta Med Port; 2020 May; 33(5):335-343. PubMed ID: 32416756
[TBL] [Abstract][Full Text] [Related]
14. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
15. How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach.
Kawsar A; Hussain K; Muinonen-Martin AJ; Fearfield L
Br J Dermatol; 2023 Oct; 189(Suppl 1):i3-i10. PubMed ID: 37903072
[TBL] [Abstract][Full Text] [Related]
16. [Cutaneous side effects of targeted cancer drugs].
Below J; Homey B; Gerber PA
Hautarzt; 2017 Jan; 68(1):12-18. PubMed ID: 27885401
[TBL] [Abstract][Full Text] [Related]
17. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
Tetzlaff MT; Nagarajan P; Chon S; Huen A; Diab A; Omar P; Aung PP; Torres-Cabala CA; Mays SR; Prieto VG; Curry JL
Am J Dermatopathol; 2017 Feb; 39(2):121-129. PubMed ID: 28134729
[TBL] [Abstract][Full Text] [Related]
18. The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes.
Hashimoto H; Ito T; Ichiki T; Yamada Y; Oda Y; Furue M
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33673164
[TBL] [Abstract][Full Text] [Related]
19. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R
Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
Keiser MF; Patel AB; Altan M
Clin Lung Cancer; 2021 May; 22(3):195-200.e1. PubMed ID: 33637416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]